Drug Shortages Plague Research

Dwindling stocks in more than a dozen cancer drugs are delaying clinical trials.

By | October 5, 2011

Some chemotherapy drugs are in short supply.FLICKR, DEREK K MILLER

Drug shortages in the United States have been growing since 2007, with several common chemotherapy drugs like doxorubicin and paclitaxel falling well below demand, Nature reported. A plethora of factors are behind the declining stocks, including the consolidation of generic drug makers, a tendency by hospitals and wholesalers to order medicines on demand rather than stockpile supplies, and manufacturing problems such as contamination from mold or glass particles. As a result, hospitals have started rationing dwindling supplies, and some clinical trials have been postponed indefinitely.

As of late August, 198 drug shortages have already been reported in the United States, according to the University of Utah’s drug information service, and of these 15 are cancer drugs required for clinical research. More than 150 trials sponsored by the National Cancer Institute (NCI) involve drugs that are in short supply. “If there was ever a national cancer-research emergency, this is it,” Robert Comis, president of the Coalition of Cancer Cooperative Groups, told Nature.

Most shortages affect old, generic drugs, but clinical trials often use these products as staples for control groups or in combination with experimental medicines. Unless patients can be ensured of completing a full dose of medication, NCI will not enroll new patients in clinical trials. A trial testing a combination of chemotherapy and antiretroviral drugs for treating advanced AIDS-related Kaposi sarcoma is on hold for at least a year because of this problem, for example. Some clinicians skirt around the issue by substituting alternative drugs when supplies of others wane, but this presents new problems with interpreting data and submitting applications to the US Food and Drug Administration for drug approval.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.